The UK NICE has issued a negative draft guidance on Nusinersen. NICE motivates its current position mainly on the grounds of the high acquisition cost of Nusinersen and the uncertainty on long term effect. This is not a final decision and a second NICE Appraisal Committee meeting is expected for October 2018. NICE’s language makes think that a further confidential price discount may change the guidance to positive. The NICE press release can be read clicking the link below:

NICE negative draft guidance on Nusinersen


Previous PostNext Post